Loa Loa is transmitted to humans by deer vectors, the vectors are bloodsucking and diurnal bites, and are found in rainforest areas in western and central Africa. After infection, a human will mate and produce more microfilariae, assuming the presence of mature male and female worms in the host. Although it has no major complications, the high microfilariae load may cause some neurological symptoms and discomfort in the ocular system may make patients uneasy. Loiasis, also known as African eyeworm, is caused by the parasitic worm Loa-Loa. Infection with this microfilaria worm causes an itchy swelling on the body, also known as Calabar bumps which prefers the rainforest-like environment of western and central Africa. Endemicity is particularly high in Cameroon, Congo, Nigeria, Gabon and the Central African Republic. One area of great concern is the fact that the endemicity of Onchocerciasis with Onchocerciasis as a bulk ivermectin therapy can lead to serious adverse effects in patients with high Loa Loa microfilariae densities and loads. This fact requires the development of more specific diagnostic tests for loa-loa so that areas or individuals at higher risk for neurological outcomes can be identified prior to microfilaricidal therapy. Although diethylcarbamazine, the standard treatment method, gives good results, it can cause serious complications when administered in standard doses to patients with high microfilariae load. A few years later, in 1778, Francois Guyost noticed worms in the eyes of West African slaves on a French ship bound for America and successfully removed the worm from a man's eye. Treatment of loiasis includes chemotherapy, in some cases surgical removal of adult worms, followed by systemic therapy.